SALINE, OMN6 clinical trials

A prospective, multinational, multicenter, randomized, sequential, double-blind, placebo-controlled, phase 2a clinical study to assess the safety and pharmacokinetics (PK) of OMN6 in hospital-acquired bacterial pneumonia (HABP) or ventilated-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii complex (ABC).

Doctors are testing a new medicine called OMN6 for severe lung infections (pneumonia) caught in hospitals or from breathing machines. This study checks if OMN6 is safe and how it works in the body. It compares OMN6 to a salt water solution (placebo) in people with specific types of pneumonia.